John F. Kouten, Chief Executive Officer

DSC_0714John F. Kouten launched JFK Communications, Inc. in 2004. JFK Communications was founded to provide strategic communications solutions for the science, healthcare and technology industries.

John has an extensive track record of public affairs experience in the pharmaceutical, biotechnology, diagnostic and medical technology industries. He has developed expertise in product public relations, corporate communications and corporate image management, crisis communications and issues management, as well as policy communications, key opinion leader development, and professional and advocacy communications.

John has a very strong combination of PR agency experience and corporate public relations experience. Further, John has extensive experience working directly with senior management on complex and sensitive corporate communications strategies and programs. He has extensive experience in strategic planning, internal consensus building and project management. John also retains strong relationships with numerous journalists reporting in the print, broadcast and online media.

From 2002 - 2004, John was a director in Johnson & Johnson’s (J&J) Global Pharmaceutical Communications group. In this capacity, he was responsible for J&J’s flagship product, PROCRIT, as well as the company’s emerging oncology portfolio, including DOXIL, Zarnestra and Yondelis. John also oversaw corporate communications and internal communications for Ortho Biotech Products, L.P. (OBI).

Prior to joining J&J, John was responsible for Worldwide Public Affairs for Bristol-Myers Squibb’s oncology, immunology and anti-infective franchises from 1996 - 2002. In this role, John managed an international team of three managers whose primary responsibilities included product public relations and issues management. During this time, John orchestrated public relations support for more than 10 FDA approvals for BMS’ flagship oncology medicine, TAXOL. John also supported many line-extension approvals for BMS’ HIV drugs.

Of note, during this time John introduced BMS to Lance Armstrong and conceived and launched the Cycle of Hope program. This program joined BMS and the Lance Armstrong Foundation together with the National Coalition for Cancer Survivorship, Cancer Care and the Oncology Nursing Society.

Prior to joining BMS, John was a manager of corporate communications at Sanofi, Inc. (1994 -1996), overseeing a broad array of communications work, including pharmaceutical, diagnostic and medical device product PR, as well as corporate and internal communications.

John began his career at Hill & Knowlton, where he worked on numerous pharmaceutical accounts. During his three years (1989 -1991) at H&K, John helped launch a number of medicines for various illnesses, including infections, viruses, mental illness and cancer. Most notably, John supported the launch of numerous anti-infectives including Augmentin, Timentin, Bactroban and Unasyn. He also played a pivotal role in the pre-launch support for E5, a monoclonal antibody for the treatment of gram-negative sepsis and septic shock.

After Hill & Knowlton, John joined Makovsky & Company (1991 - 1994) where he supported the launch of numerous products for Abbott Labs and Pfizer. Of note, John oversaw the pre-launch, launch and post-launch public relations support for Biaxin and Omniflox. While at Makovsky, John won the prestigious Silver Anvil award for his work on the launch of Metastron, a pain treatment for cancer patients.

John graduated cum laude from Rowan University in 1989 with a BA in communications.